Chongqing Zhifei Biological Products (300122.SZ): The DeGu Aconite Insulin Injection (CA508 Injection) has obtained the Phase III clinical trial summary report.

17:42 29/12/2025

Chinapeptides (300122.SZ) announced that the company recently received the Phase III clinical trial summary report for the DeGummen Winter Double Insulin Injection (CA508 injection) developed by its subsidiary Chongqing Chen'an Biopharmaceutical Co., Ltd. The effectiveness and safety of the DeGummen Winter Double Insulin Injection (CA508 injection) developed by Chen'an Biopharmaceutical are equivalent to the original drug DeGummen Winter Double Insulin Injection (NovoLog), meeting the design requirements for effectiveness and safety evaluation outlined in the "Guiding Principles for Clinical Trials of Diabetes Therapeutics and Biologics."

Chongqing Zhifei Biological Products (300122.SZ) announced that the company recently received the Phase III clinical trial summary report for the Dezhu Mendong Double Insulin Injection (CA508 injection) developed by its subsidiary Chongqing Chenan Biological Pharmaceutical Co., Ltd. The CA508 injection developed by Chenan Biological is comparable in effectiveness and safety to the original drug Dezhu Mendong Double Insulin Injection (Novo Nordisk), meeting the design requirements for efficacy and safety evaluation in the "Guiding Principles for Clinical Trials of Diabetes Therapeutics and Biologics".

Northeast: Music ecosystem giant NETEASE MUSIC (09899) benefits from rapid industry growth.

Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.

US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.

Northeast: Music ecosystem giant NETEASE MUSIC (09899) benefits from rapid industry growth.

Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.

US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.